Document:

<PAGE>   1
                                                                   Exhibit 10.24

  CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
                EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                          SALES FORCE WORK ORDER # 8475

                 EFFECTIVE DATE OF WORK ORDER: OCTOBER 10, 2000

This Sales Force Work Order (the "Work Order") is entered into between The
Medicines Company ("TMC") and Innovex LP ("Innovex"), pursuant to the Master
Services Agreement, having an Effective Date of October 10, 2000, between TMC
and Innovex (the "Master Services Agreement"), and is subject to all the terms
and conditions set forth therein, except as may be otherwise expressly provided
herein. All capitalized terms used in this Work Order not otherwise defined
herein shall have the same definition as ascribed to that term in the Master
Services Agreement.

BRIEF DESCRIPTION OF SALES FORCE PROJECT:

Innovex is providing TMC with a field sales force of 52 Sales Representatives
and 2 Field Coordinators, together with the support of an Innovex National Sales
Director, a National Sales Manager and an Administrative Assistant, to support
TMC's sales and marketing efforts on TMC's pharmaceutical product AngiomaxTM.
This Work Order covers a two-year period as described below.

PROJECT TEAMS:

TMC CONTACT PERSON:  PAUL PUCCIONI
           ADDRESS:  5 SYLVAN WAY
                     PARSIPPANY, NJ 07054
             PHONE:  973-401-6460
               FAX:  973-656-9898

INNOVEX NATIONAL SALES MANAGER/NATIONAL SALES DIRECTOR:
                     BOB MCGOWAN/PHIL SALIMBENE
           ADDRESS:  10 WATERVIEW BLVD.
                     PARSIPPANY, NJ 07054
             PHONE:  973-257-4500
               FAX:  973-257-4581

Routine correspondence relevant to the operation of the sales force should be
sent to the above-named contact persons. All notices or similar communications
in regard to the terms or a change of terms of this Work Order are to be sent to
the parties named in the Master Services Agreement - Section 16. Notices.

                                       1
<PAGE>   2

PROJECT TERM AND KEY DATES:

Project Start Date                           October 16, 2000
Field Coordinator Start Date                 October 16, 2000
Sales Representative Start Date              December 11, 2000
Initial Live Training Dates                  January 4, 2001
Project End Date (Last Day Worked)           December 10, 2002

"Project Term" shall mean the period of time beginning on the Project Start Date
and ending on the Project End Date. Any renewal of the Project or extension of
the Project End Date shall be negotiated by the parties at least ninety (90)
days before the Project End Date, and shall be effective when agreed in writing.

DEFINITIONS

1.   "Day Worked" shall mean a day during which a Sales Representative details
     Customers, or attends scheduled company training and/or specifically
     designated home study. A "Day Worked" by a Field Coordinator shall mean a
     day during which the Field Coordinator performs duties and responsibilities
     described in the Work Order. Days Worked shall not include days on leave,
     holidays, sick days, vacations or any Saturday or Sunday, except for
     training or meeting days scheduled on a Saturday or Sunday. The average
     number of days worked in a twelve month period shall be two hundred
     thirty-two (232).

2.   "Detail" shall mean an interactive face-to-face contact by a Sales
     Representative with a Customer, during which a promotional message
     involving the Product is given in accordance with the Promotional Program.
     When used as a verb, "detail," "details" and "detailed" shall mean to
     engage in a Detail as defined herein.

3.   "Customer" shall mean physicians and other health care professionals
     legally authorized to write prescriptions for pharmaceutical products or
     otherwise have the ability to impact decisions to utilize TMC Product in
     "Target Accounts". This includes but is not limited to: Interventional
     Cardiologists, cath lab personnel, hospital pharmacists, P & T committee
     members and hospital administrators.

4.   "Product" shall mean the TMC pharmaceutical products specifically
     identified in this Work Order or any other product whose promotion and
     detailing is assigned to Innovex by mutual agreement with TMC.

5.   "Promotional Expense Budget" shall mean the funding and guidelines for use
     of such funding that are provided by TMC for use by the Sales Force when
     detailing Product.

6.   "Promotional Material" shall mean the Product labeling and package inserts,
     sales aids and detailing materials developed and provided by TMC, and other
     promotional support items provided by TMC to Innovex, for use in promotion
     of the Product.

                                       2
<PAGE>   3

7.   "Promotional Program" shall mean the marketing plan, strategy and
     promotional message for the Product, which will include use of the
     Promotional Material and the Promotional Expense Budget.

8.   "Sales Force" shall mean the Sales Representatives, Field Coordinators,
     National Sales Director, and National Sales Manager, individually and as a
     group, that have been assigned to deliver Details of the Product in
     accordance with the terms of this Agreement.

9.   "Sales Representative" shall mean an Innovex employee who has been trained
     and equipped to detail Customers.

10.  "Target Customer" shall mean one of the Customers specifically identified
     by TMC within a Sales Representative's territory to be detailed by the
     Sales Representative.

11.  "Target accounts" shall mean a specially identified account by TMC within a
     Sales Representative's territory to be detailed by the Sales
     Representative.

12.  "Territory" shall mean the United States and Puerto Rico. In connection
     with an individual Sales Representative, the territory shall be the
     geographic area assigned to the individual Sales Representative.

INNOVEX RESPONSIBILITIES AND OBLIGATIONS

1.   SALES FORCE. The Sales Force will be composed of the following Innovex
     employees:

              NUMBER                        POSITION TITLE
              ------                        --------------
                52         Sales Representatives
                 2         Field Coordinators
            1 (.1 FTE)     National Sales Director
            1 (.1 FTE)     National Sales Manager
            1 (.2 FTE)     Project Administrator (Administrative Assistant)

     TMC may request that Innovex provide additional Sales Representatives, by
     submitting a written request in substantially the form attached hereto as
     Exhibit 1, ("Additional Sales Representative Request Form"). As the total
     number of Sales Representatives increases for the Sales Force, additional
     Field Coordinators will also be increased in order to maintain a target
     ratio of Field Coordinators to Sales Representatives of approximately 1:27.

2.   RECRUITMENT. Innovex shall be responsible for recruitment and
     re-recruitment (replacement) of the Sales Representatives and Field
     Coordinators in accordance with the Sales Force Qualifications described
     below. Innovex shall be responsible for the cost of recruitment, background
     checks and drug screens. If TMC elects to participate in the final
     selection of members of the Sales Force, TMC shall approve or disapprove
     qualified candidates within five

                                       3
<PAGE>   4

     (5) business days after each qualified candidate is submitted to TMC for
     final selection. A "qualified candidate" must meet the Sales Force
     Qualifications. TMC shall be entitled to a recruitment rebate in the amount
     of for each Sales Representative or Field Coordinator hired by Innovex for
     the Sales Force who was referred to Innovex by TMC, prior to the tenth day
     of a territory vacancy; provided, however, that TMC shall not be eligible
     for a rebate in connection with any individual referred to Innovex by TMC
     who was already, at the time of the referral, included in the Innovex
     database as a candidate for employment, and Innovex can provide
     satisfactory evidence of such database inclusion. In addition, the rebate
     shall be reduced by the amount of actual expenses incurred by Innovex for
     recruitment and advertising for the territory, prior to the date of the TMC
     referral.

3.   SALES FORCE QUALIFICATIONS. Innovex will exercise best efforts to recruit
     from a diverse candidate base. A qualified candidate for Sales
     Representatives shall meet the following minimum qualifications: four-year
     college degree (B.A., B.S. or equivalent); 1-2 years hospital selling of
     pharmaceuticals (preferred) or devices to cardiologists/cath labs/ERs. A
     qualified candidate for Field Coordinator shall meet the following minimum
     qualifications: four-year college degree (B.A., B.S. or equivalent); 2
     years pharmaceutical sales experience, 2 years management experience. The
     three Salary Tiers for TMC Representatives and the criteria they must
     satisfy are provided in the Angiomax Representative Profile, attached to
     this Work Order.

4.   POSITION DESCRIPTIONS AND DUTIES.Innovex shall manage, supervise and
     evaluate the performance of the National Sales Manager, National Sales
     Director, Field Coordinators and Sales Representatives in accordance with
     the responsibilities and duties identified below. All Sales Force employees
     shall demonstrate the following: work ethic and integrity; planning,
     organizing and territory management skills; strong interpersonal skills;
     excellent communication skills; critical thinking and analysis; problem
     solving; decisiveness; sound judgment; customer-focused selling skills;
     basic computer skills; ability to listen and learn.

     SALES REPRESENTATIVES
          -    Generate sales within an assigned territory
          -    Maintain and update current and prospective target physician
               profiles
          -    Keep current with market knowledge and competitive
               products
          -    Maintain a professional image for TMC and TMC Products
          -    Participate in all training and sales meetings
          -    Plan and organize territory to meet sales and call targets
          -    Make sales presentations (details) - individual, one-on-one,
               in-services
          -    Comply with PDMA
          -    Make complete, accurate and timely submission of all
               time-keeping, call activity and expense reports
          -    Compliance with Promotional Program, and proper use of
               Promotional Materials and Promotional Expense Budgets

                                       4
<PAGE>   5

     NATIONAL SALES MANAGER/NATIONAL SALES DIRECTOR

          -    Recruit, interview and select Field Coordinators
          -    Handle periodic performance review, personnel issues, discipline
               and termination of Field Coordinators
          -    Communicate with TMC field/regional managers on regular and
               timely basis
          -    Assist with the planning and delivery of training, and periodic
               sales meetings
          -    Review and approve expense reports; monitor compliance with
               expense policies.
          -    Monitors compliance with Promotional Program, and proper use of
               Promotional Materials and Promotional Expense Budgets
          -    Monitors compliance with PDMA

     FIELD COORDINATORS

          -    Assist with recruitment of Sales Representatives
          -    Handle periodic performance review, personnel issues, discipline
               and termination of Sales Representatives
          -    Review and approve expense reports; monitor compliance with
               expense policies
          -    Conduct field visits with Sales Representatives as schedule
               permits in order to: assess and monitor field activity and work
               schedules; to monitor and manage field reporting, including call
               reporting; to implement performance or disciplinary plans.
          -    Communicate with TMC field/regional managers on regular and
               timely basis
          -    Assist with the planning and delivery of training, and periodic
               sales meetings, if necessary

5.   SALES FORCE COMPENSATION; BENEFITS. Innovex shall compensate the Sales
     Force employees with a combination of salary and variable incentive
     (bonus). Innovex and TMC, shall mutually establish a target average salary
     and salary matrix, which recognizes greater experience and training, and
     preferred selection criteria notwithstanding section 5.4 of the Master
     Agreement. The terms and conditions of a variable incentive compensation
     plan ("Incentive Plan") shall be mutually determined by Innovex and TMC,
     including eligibility criteria and performance targets. The Incentive Plan
     may also include incentive awards such as trips and prizes. Innovex shall
     administer the Incentive Plan, determine eligibility and pay the incentive
     compensation and awards, in accordance with the Incentive Plan provided no
     payments are made under the Incentative Plan without the prior written
     consent of TMC. Sales Force employees shall be eligible to receive an auto
     allowance, and shall be entitled to participate in the Innovex employee
     benefit plans for health and dental care, 401K, employee stock purchase and
     stock ownership plans, in accordance with company eligibility criteria.

6.   TRAINING AND PERIODIC SALES MEETINGS. Innovex shall assist TMC with
     organizing and delivering initial training of the Sales Force, backfill
     training of replacement Field Coordinators and Sales Representatives and
     all follow-up training, including periodic sales meetings.

7.   PROMOTIONAL ACTIVITIES. Innovex shall be responsible for managing and
     monitoring the promotional activities of the Sales Force, in strict
     adherence to the Promotional Program and using only the Promotional
     Materials provided by TMC. Sales Representatives shall not be

                                       5
<PAGE>   6

     permitted to develop, create or use any other promotional material or
     literature in connection with the promotion of the Product. Sales
     Representatives will be required to immediately cease the use of any
     Promotional Materials when Innovex is instructed to do so by TMC. Innovex
     shall monitor that Promotional Materials are not changed, (including,
     without limitation, by underlining or otherwise highlighting any text or
     graphics or adding any notes thereto) by the Sales Representatives. Sales
     Representatives shall be required to limit their statements and claims
     regarding the Product, including as to efficacy and safety, to those which
     are consistent with the Product labels, package inserts and Promotional
     Materials. The Sales Representatives shall not be permitted to add, delete
     or modify claims of the efficacy or safety in the promotion of the Product,
     nor shall the Sales Representatives be permitted to make any untrue or
     misleading statements or comments about the Products or any TMC competitors
     or competitor products.

8.   PROJECT REPORTS. Innovex shall provide TMC a monthly Project report, which
     shall include: (i) headcount, reported nationally, by region/district;
     vacancy rates, turnover, personnel transfers to TMC, status of
     recruitment/hiring; (ii) Project status, milestones, and progress toward
     achieving objectives; (iii) financial accountability, tracking expenses
     against budget; and (iv) call reporting, as contemplated by item 9 below.

9.   REPORTING BY SALES REPRESENTATIVES. Sales Representatives shall be required
     to report all field activities and expenditures in a manner that is timely,
     accurate and honest, and in accordance with policies and procedures for the
     applicable reporting systems. Innovex Field Coordinators shall routinely
     reinforce the importance of compliance with the reporting guidelines and
     policies (e.g. call reporting, promotional budget expenditures, travel
     expenses). Newly hired Sales Representatives shall receive training on the
     reporting systems, guidelines and policies during the initial sales
     training program.

10.  ITMS AND CALL REPORTING. Innovex shall provide the Innovex Territory
     Management System, including automated call reporting. Innovex shall equip
     the Sales Force with computer hardware and software, including a
     combination printer/fax/copier, and shall bear the cost of database and
     system administration, licenses, access to data/replication lines, help
     desk support, and training of the Sales Force in proper use of the
     computers and software. Sales Representatives shall not distribute samples
     of TMC products and Innovex shall have no responsibility for sample
     accountability.

11.  CELL PHONES. Innovex shall provide cell phones for the Sales
     Representatives.

CUSTOMER RESPONSIBILITIES AND OBLIGATIONS

1.   PROMOTIONAL PROGRAM AND PROMOTIONAL MATERIALS. TMC shall be responsible for
     providing a Promotional Program, Promotional Materials and Promotional
     Expense Budget that (i) will not involve the counseling or promotion of a
     business arrangement that violates federal or state law; (ii) will be in
     compliance with the AMA Guidelines on Gifts to Physicians from Industry;
     and (iii) shall not require or encourage the Sales Representatives to
     offer, pay, solicit

                                       6
<PAGE>   7

     or receive any remuneration from or to Prescribers to induce referrals or
     purchase of TMC Product. TMC shall be responsible for providing written
     guidelines for proper use of the TMC's Promotional Expense Budget.

2.   TRAINING AND PERIODIC SALES MEETINGS.
     TMC shall be responsible for the following:

     -    Programming and materials for initial Sales Force training of 7-9 days
          duration. The initial training agenda shall include 8 hours designated
          for Innovex training regarding personnel management, compensation and
          benefits and field administration.

     -    Programming, materials and facilities for periodic sales meetings of
          2-3 days duration or otherwise as agreed by the parties.

2.   PDMA. TMC and Innovex shall cooperate in connection with PDMA compliance
     investigations and audits. TMC will provide to Innovex for review and
     comment, a copy of any PDMA compliance report in connection with the Sales
     Force, prior to filing with the FDA.

3.   SALES DATA. TMC shall be solely responsible for obtaining historic and
     ongoing sales data regarding TMC Products.

4.   BUSINESS CARDS; PORTFOLIOS. Innovex shall supply the Sales Force with
     business cards, the content of which shall be subject to approval by TMC,
     such approval not to be unreasonably withheld. Innovex shall supply the
     Sales Force with detail portfolios.

5.   SALES FORCE TRAVEL EXPENSES. TMC shall be responsible for the following
     Sales Force travel, lodging and meal expenses, when necessary and actually
     incurred by the Sales Force (in the amounts authorized in a mutually agreed
     Sales Force travel expense budget):

     -    Travel expenses of Sales Force in connection with all training and
          periodic sales meetings

     -    Travel expenses for Field Coordinators and National Sales Manager in
          connection with field management in the territories.

6.   SALES & MARKETING SUPPORT. TMC-employed Regional Managers shall provide
     sales and marketing support and direction to the Sales Representatives. TMC
     Regional Managers shall not be involved with the discipline and work
     evaluations of the Sales Force except in an advisory capacity.

FEES AND PASS-THROUGH EXPENSES

1.   a. PASS-THROUGH EXPENSES. "Pass-Through Expenses" shall mean the reasonable
     and necessary out-of-pocket costs and expenses actually incurred by Innovex
     in providing Services, in accordance with a mutually agreed written budget
     or the express terms of the Work Order.

                                       7
<PAGE>   8

   CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
                EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

     b. DAILY FEES. TMC shall pay Innovex a Daily Fee for each Day Worked by
     Sales Representatives and Field Managers during the Project Term. The Daily
     Fees and total estimated Daily Fees during the Project Term are stated in
     the following tables:

YEAR ONE (10/16/2000 TO 12/10/2001)

<TABLE>
<CAPTION>

                                                            ESTIMATED      ESTIMATED
                                                           DAYS WORKED    TOTAL DAYS    ESTIMATED
SALES FORCE POSITIONS           NUMBER      DAILY RATE        WORKED        WORKED      TOTAL FEES
---------------------           ------      ----------     -----------    ----------    ----------
<S>                         <C>          <C>           <C>            <C>           <C>

Sales Representatives             52          $[**]            232          12,064        $[**]
---------------------------------------------------------------------------------------------------
Field Coordinators                 2          $[**]            251             502        $[**]
---------------------------------------------------------------------------------------------------
Nat'l Sales Director (.1 FTE)      1                                                       [**]
---------------------------------------------------------------------------------------------------
Nat'l Sales Manager (.1 FTE)       1                                                       [**]
---------------------------------------------------------------------------------------------------
Project Admin. (.2 FTE)            1                                                       [**]
---------------------------------------------------------------------------------------------------
                                                              ESTIMATED TOTAL FEES        $[**]
---------------------------------------------------------------------------------------------------
</TABLE>

YEAR TWO (12/11/2001 TO 12/10/2002)

<TABLE>
<CAPTION>

                                                            ESTIMATED      ESTIMATED
                                                           DAYS WORKED    TOTAL DAYS    ESTIMATED
SALES FORCE POSITIONS           NUMBER      DAILY RATE        WORKED        WORKED      TOTAL FEES
---------------------           ------      ----------     -----------    ----------    ----------
<S>                         <C>          <C>           <C>            <C>           <C>

Sales Representatives             52          $[**]            232         12,064         $[**]
---------------------------------------------------------------------------------------------------
Field Coordinators                 2          $[**]            232            464         $[**]
---------------------------------------------------------------------------------------------------
Nat'l Sales Director (.1 FTE)      1                                                       [**]
---------------------------------------------------------------------------------------------------
Nat'l Sales Manager (.1 FTE)       1                                                       [**]
---------------------------------------------------------------------------------------------------
Project Admin. (.2 FTE)            1                                                       [**]
---------------------------------------------------------------------------------------------------
                                                              ESTIMATED TOTAL FEES        $[**]
---------------------------------------------------------------------------------------------------
</TABLE>

2.   TAKE-ON FEE. Innovex shall charge TMC a fee for each Sales Representative
     or Field Coordinator that becomes employed by TMC or a TMC Affiliate during
     the first 12 months of such employee's provision of services to TMC under
     the terms of this Work Order. The fee shall be equal to [**] percent
     ([**]%) of the employee's then current Innovex annual salary if the
     employee is taken on during the first six months of such provision of
     services and [**] percent ([**]%) during the next six months. The fee shall
     be due and payable upon the employee's commencement of employment with TMC.
     There shall be no take-on fee for any Sales Representative or Field
     Coordinator that becomes employed by TMC or a TMC Affiliate after such
     employee has provided twelve months of services under the terms of this
     Work Order. In addition, if the turnover rate exceeds [**] percent ([**]%)
     during Year One of the Project Term (i.e. turnover of [**] more territories
     between 10/16/2000 and 12/10/2001, TMC shall have the option to rollover
     and employ the entire Sales Force without obligation to pay any take-on fee
     in connection with such rollover; provided, however, the exercise of this
     option by TMC shall not shorten the termination notice provisions of
     Section 11 of the Master Agreement. The calculation of turnoiver shall
     exclude

                                       8
<PAGE>   9

  CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
                EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

     (i) any Sales Representative that is hired by TMC or a TMC Affiliate; and
     (ii) any Sales Representative that is terminated or removed from the Sales
     Force at the request of TMC.

3.   INCENTIVE PLAN ADMINISTRATION. TMC shall pay Innovex an amount equal to (i)
     the amount of all incentive compensation earned by Sales Representatives
     and Field Coordinators in accordance with the terms of the Incentive Plan;
     and (ii) an amount equal to [**]% of the incentive compensation for
     Innovex's employer costs (payroll taxes).

4.   PAYMENT SCHEDULE. Innovex shall invoice TMC monthly for all Daily Fees,
     Take-on Fees and Pass-Through Expenses. At the end of each calendar month
     Innovex shall provide TMC a list of the billable Sales Force personnel and
     the total number of Days Worked multiplied by the respective Daily Fee
     rate. Innovex shall invoice TMC in advance for all incentive compensation
     and related employer costs, and the incentive compensation shall be paid to
     the Innovex Personnel by Innovex only after TMC pays to Innovex the amount
     of the applicable incentive compensation invoices.

5.   RECOVERY OF COSTS UPON EARLY TERMINATION. If TMC terminates this Work Order
     before December 10, 2001, then in addition to all Fees and Pass-through
     Expenses that are payable in accordance with Section 11.5 of the Master
     Services Agreement, TMC shall also pay to Innovex (a) any non-cancelable
     obligations incurred in accordance with the terms of this Work Order, net
     of recoveries (e.g. cancellation fees, computer lease termination fees);
     and (b) the amount of $[**] for each month remaining (prorated for partial
     months) prior to December 10, 2001 (at the conclusion of the contractual
     notice period), to compensate Innovex for unamortized costs of recruitment,
     training, and ITMS start-up.

6.   Fee Deposit. In accordance with the terms of the Letter of Intent, TMC has
     paid Innovex the amount of $[**] on October 16, 2000, and TMC shall pay an
     additional sum of $[**] on or before December 31, 2000. This amount shall
     continue to be held by Innovex and will be credited towards the invoices
     for Fees and Pass-Through Expenses for the final two months of the Project
     Term and upon the early termination of this Work Order.

7.   EXPENSE ALLOCATION CHART. The financial responsibility of Innovex and TMC
     for expenses and costs of Sales Force operation shall be allocated in
     accordance with the terms of this Work Order, which are summarized for
     illustrative purposes in the "Sales Force Expense Allocation" chart
     (Attachment A).

                                       9
<PAGE>   10
            Confidential Materials omitted and filed separately with
      the Securities and Exchange Commission. Asterisks denote omissions.

SPECIAL TERMS

1.   Notwithstanding anything in this Work Order or the Master Services
     Agreement to the contrary, TMC shall not be allowed to terminate this Work
     Order or the Master Services Agreement on earlier than 90 days notice due
     to any delay or failure of AngiomaxTM to be approved by the FDA.

2.   The Daily Fees recited above are conditioned upon Innovex paying the
     following average annual salaries, using a combination of the three Salary
     Tiers as outlined in the Angiomax Representative Profile (Attachment B):

                                     PER REP.                 PER F.C.
                                     --------                 --------
     Projected Salaries          $[**] in Year One        $[**] in Year One
     ----------------------------------------------------------------------
                                 $[**] in Year Two        $[**] in Year Two

     Beginning with the monthly invoice for December 2000 (to be prepared in
     January 2001), Innovex will calculate the average annual salary actually to
     be paid to Sales Representatives and Field Coordinators during Year One,
     and shall make an appropriate adjustment to the Daily Fees, provided,
     however, the average annual salary per Sales Representative does not exceed
     $[**] in Year One or $[**] in Year Two. At the end of March 2001 and
     quarterly thereafter, Innovex will reconcile its actual average annual
     salary against the projected salary, above, and make an appropriate
     adjustment to the Daily Fees.

3.   Innovex shall be entitled to earn in connection with the sales and
     marketing services provided pursuant to this Work Order up to $[**] in
     incentive compensation based on the percentage of sales achieved over a Net
     Sales Target as described in Chart II below. The applicable Net Sales
     Target shall be as agreed by the parties in good faith. Should the parties
     fail to agree on an applicable Net Sales Target for either Year One or Year
     Two prior to the time Sales Representatives begin detailing Customers
     during that year, then Innovex's incentive compensation for that year shall
     be $[**] (without regard to whether or not actual sales meet or exceed a
     sales target). The incentive compensation shall be payable to Innovex on or
     before 3/1/2002. Year Two incentive compensation shall be payable to
     Innovex on or before 3/1/2003. In the event the Agreement is terminated
     during Year One or Year Two, the applicable Net Sales Target and incentive
     compensation due for that year shall be prorated as outlined in the example
     contained in Chart I below.

                                       10
<PAGE>   11

  CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
                EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

     CHART I
     EXAMPLE INCENTIVE: EARLY TERMINATION

     Termination Date                                           10/1/01
     ---------------------------------------------------------------------------
     Innovex Field Time in 2001                       9 months (1/4/01- 9/30/01)
     ---------------------------------------------------------------------------
     Proration Factor                                    0.75 (9 of 12 months)
     ---------------------------------------------------------------------------
     2001 Net Sales Target                                       $[**]
     ---------------------------------------------------------------------------
     2001 Net Sales Actual                                       $[**]
     ---------------------------------------------------------------------------
     % of Sales Target                                            116%
     ---------------------------------------------------------------------------
     Payout Schedule                                             $[**]
     ---------------------------------------------------------------------------
     Payment due Innovex                                     $[**] x 0.75)
     ---------------------------------------------------------------------------

     CHART II

     % of  Sales v.  Net        Incentive Compensation Payable to Innovex
     Sales Target               for Actual Sales vs. Target
     ---------------------------------------------------------------------------
                                                           Total Amount Payable
     ---------------------------------------------------------------------------
      100% (target)                 $0                     $0
     ---------------------------------------------------------------------------
      102%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      104%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      106%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      108%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      110%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      112%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      114%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      116%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      118%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      120%+                         $[**]                  $[**]
     ---------------------------------------------------------------------------

                                       11

<PAGE>   12

In Witness Whereof, TMC and Innovex have caused this Work Order # 8475 to be
duly executed on their behalf by their authorized representatives and made
effective as of Effective Date of Work Order appearing above.

ACCEPTED AND AGREED TO BY:

THE MEDICINES COMPANY               INNOVEX LP
                                    By: Innovex America Holding
                                        Company, its General Partner

/s/ Thomas P. Quinn                 s/s John E. Monahan
----------------------------        -----------------------------
By:    Thomas P. Quinn              By:    John E. Monahan
Title: VP Sales and Marketing       Title: President
Date:  November 17, 2000            Date:  November 17, 2000

                                       12

<PAGE>   13

                     ATTACHMENT A TO SALES FORCE WORK ORDER
                         SALES FORCE EXPENSE ALLOCATION
                                  OCTOBER, 2000
                                 PROJECT # 8475

<TABLE>
<CAPTION>

------------------------------------------------------------------------------------------------------------------------
                                                                             INNOVEX                              TMC
                                                                             DIRECT         PASS-THROUGH         DIRECT
                          CATEGORY                                          EXPENSES          EXPENSES          EXPENSES
------------------------------------------------------------------------------------------------------------------------
<S>                                                                      <C>            <C>                <C>

Salary, including payroll taxes, for Sales Representatives, Field               X
Coordinators, National Sales Manager
------------------------------------------------------------------------------------------------------------------------
Incentive compensation (bonus) for Sales Representatives & Field                                  X
Coordinators, including payroll taxes
------------------------------------------------------------------------------------------------------------------------
Benefits package, including (401k), ESOP, ESPP, medical, dental, Rx,            X
vacation, holidays
------------------------------------------------------------------------------------------------------------------------
Auto Costs, including monthly allowance, mileage reimbursement, parking and     X
tolls.
------------------------------------------------------------------------------------------------------------------------
Basic Business Expenses, including phone, paper supplies, postage and voice     X
mail.
------------------------------------------------------------------------------------------------------------------------
Business Cards & Portfolio; Cell Phones                                         X
------------------------------------------------------------------------------------------------------------------------
Call Reporting; ITMS                                                            X
------------------------------------------------------------------------------------------------------------------------
Computers for Sales Force Representatives, including software,                  X
helpdesk support, data/replication lines; combo fax/printer/copier
------------------------------------------------------------------------------------------------------------------------
Infrastructure support (operations, HR, finance, legal)                         X
------------------------------------------------------------------------------------------------------------------------
Liability Insurance: employment, workers comp, E & O, CGL, auto                 X
------------------------------------------------------------------------------------------------------------------------
Recruitment and re-recruitment, includes drug screens, background and           X
motor vehicle checks
------------------------------------------------------------------------------------------------------------------------
Meetings:  TMC national, regional and district meetings; product                                                   X
launches
------------------------------------------------------------------------------------------------------------------------
Promotional Expense Budget (access money)                                                         X
------------------------------------------------------------------------------------------------------------------------
Promotional Program and Promotional Materials (sales aids)                                                         X
------------------------------------------------------------------------------------------------------------------------
Promotional marketing expenses, including sales data                                                               X
------------------------------------------------------------------------------------------------------------------------
Training program, materials and facilities; initial and follow-up                                                  X
------------------------------------------------------------------------------------------------------------------------
Travel Expenses (air, hotel & meals) for Sales Reps, Field
Coordinators, National Sales Manager, National Sales Director for:
*Interviewing                                                                   X
*Training                                                                                         X
*Territory travel for field management purposes                                                   X
------------------------------------------------------------------------------------------------------------------------
</TABLE>

                                       13

<PAGE>   14

                       EXHIBIT 1 TO SALES FORCE WORK ORDER
                  ADDITIONAL SALES REPRESENTATIVE REQUEST FORM

This Request for Additional Sales Representative is issued pursuant to the
Master Services Agreement between TMC and Innovex, dated October 10, 2000 and
Work Order # 8475, dated October 10, 2000. (Sales Force # 8475).

--------------------------------------------------------------------------------
PART 1                                 To be completed by TMC
                                       Attach any relevant, helpful information
--------------------------------------------------------------------------------
NUMBER OF SALES REPRESENTATIVES
REQUESTED
--------------------------------------------------------------------------------

TERRITORY LOCATION(S)
--------------------------------------------------------------------------------

REQUESTED START DATE
--------------------------------------------------------------------------------

AUTHORIZED CUSTOMER REPRESENTATIVE     Signature: ___________________________
SUBMITTING REQUEST                     Name:
                                       Title:
                                       Date:
                                       Phone:
                                       Fax:

--------------------------------------------------------------------------------
PART 2                                 TO BE COMPLETED BY INNOVEX
                                       INNOVEX SHALL RESPOND WITHIN TEN (10)
                                       BUSINESS DAYS AFTER RECEIPT OF THE
                                       ADDITIONAL SALES REPRESENTATIVES REQUEST.
--------------------------------------------------------------------------------

This Additional Sales Representative   Request is Accepted, and Recruitment
Request Form was Received by Innovex   shall begin immediately:
on the following date:                 ______________________________________
                                       (sign and date)
         _____________________         Contact Person:
                                       Phone:
--------------------------------------------------------------------------------

                                       REQUEST IS NOT ACCEPTED (identify above
                                       information which must be clarified or
                                       changed before Request may be accepted
                                       by Innovex):

                                       _______________________________________
                                       (sign and date)
                                       Contact Person:
                                       Phone:
--------------------------------------------------------------------------------

                                       14

<PAGE>   15

  CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
                EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                   ATTACHMENT B TO THE SALES FORCE WORK ORDER
                                    ANGIOMAX
                             REPRESENTATIVE PROFILE

Tier 1 Candidate   ($[**] - $ [**])
   -  3 - 5yrs. pharmaceutical sales experience
   -  2 years hospital sales experience
   -  2+ years cardiovascular background
   -  Sold Cath Lab drugs
      -  GP IIb/IIIa inhibitors
      -  Plavix
      -  Ticlid
      -  Thrombolytics
         -  Activase
         -  Retavase
         -  Streptase
         -  Eminase
         -  Abbokinase (best chance)
      -  LMWH
         -  Lovenox
         -  Fragmin
         -  Normiflo
         -  Orgaran
   -  Or sold Cath Lab devices
         -  Catheters
         -  Stents
         -  Sheaths
         -  Commodity cath lab sales
         -  Etc.
   -  Cath Lab contacts via other cardiology hospital-based pharmaceutical sales
         -  Pfizer/Parke Davis
         -  BMS
         -  Etc.
   -  Proven sales track record - sales awards and sales contest winners

TIER 2 CANDIDATE ($[**] - $ [**])
   -  2 - 3yrs. pharmaceutical sales experience
   -  Cardiovascular experience preferred
   -  Smaller pharma. cardiovascular hospital representatives
   -  Big pharma. cardiovascular field representatives
      -  Statins
      -  Aces
      -  AII's
      -  CCB's
      -  Antihypertensives
   -  Contrast imaging sales representatives

                                       15

<PAGE>   16

  CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
                EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

-  Hospital based personnel with cardiovascular background
   -  Pharmacists
   -  CCU nurses
   -  Cath lab nurses
   -  Cath Lab techs

 TIER 3 CANDIDATE ($[**] - $ [**])

-  Top-notch sales people that want to break into the industry
-  Nurses

                                       16<PAGE>   1
                                                                   EXHIBIT 10.26

                              EMPLOYMENT AGREEMENT
                              --------------------

     THIS EMPLOYMENT AGREEMENT (the "Agreement"), made this 1st day of April, is
entered into by The Medicines Company, a Delaware corporation with its principal
place of business at One Cambridge Center, Cambridge, Massachusetts 02142 (the
"Company"), and Thomas Quinn, residing at 325 Independence Drive, Orchard Park,
New York 14127 (the "Employee").

     The Company desires to employ the Employee, and the Employee desires to be
employed by the Company. In consideration of the mutual covenants and promises
contained herein, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged by the parties hereto, the parties
agree as follows:

     1.   TERM OF EMPLOYMENT. The Company hereby agrees to employ the Employee,
and the Employee hereby accepts employment with the Company, upon the terms set
forth in this Agreement, for the period commencing on April 1, 2000 (the
"Commencement Date") and ending on April 1, 2001 (such period, as it may be
renewed as provided in the following sentence, the "Employment Period"), unless
sooner terminated in accordance with the provisions of Section 4. The Employment
Period shall automatically be renewed for successive one (1) year periods unless
either the Employee or the Company provide written notice of non-renewal to the
other party at least ninety (90) days prior to the expiration of the then
current term.

     2.   TITLE; CAPACITY. The Employee shall serve as Vice President or in such
other position as the Company or its Board of Directors (the "Board") may
determine from time to time. The Employee shall be based at the offices of Stack
Pharmaceuticals, Inc., 5 Sylvan Way, Parsippany, New Jersey, unless otherwise
agreed by the parties. The

                                       1
<PAGE>   2

Employee shall be subject to the supervision of, and shall have such authority
as is delegated to him by David Stack, Senior Vice President of the Company (or
such officer of the Company as may be designated by the Board).

The Employee hereby accepts such employment and agrees to undertake the duties
and responsibilities inherent in such position and/or such other duties and
responsibilities as David Stack (or the Board or its designee) shall from time
to time reasonably assign to him. The Employee agrees to devote an average of 24
hours per week to the business and interests of the Company during the
Employment Period. The Company and the Employee generally anticipate that such
hours shall be provided in the form of three business days per week; provided
that (i) the Company and the Employee shall agree upon a work plan on a monthly
basis setting forth the parties' expectations as to when the Employee shall
provide his services to the Company during the forthcoming month and (ii) the
Employee shall have the right to fluctuate his working hours from week to week
as long as the Employee works a total of 288 hours during each three-month
period during the Employment Period. The Employee shall provide the Company on a
monthly basis with a written report setting forth the number of hours/days
worked by the Employee in the previous month. The Employee agrees to abide by
the rules, regulations, instructions, personnel practices and policies of the
Company and any changes therein which may be adopted from time to time by the
Company except as provided in these agreements. The Employee acknowledges
receipt of copies of all such rules and policies committed to writing as of the
date of this Agreement.

     3.   COMPENSATION AND BENEFITS.

          3.1  SALARY. The Company shall pay the Employee, in semi-monthly
installments, an annual base salary of $120,000 for the one-year period
commencing on

                                       2
<PAGE>   3
the Commencement Date. Such salary shall be subject to adjustment thereafter as
determined by the Board, but shall not be reduced below the amount set forth
above without the Employee's consent.

          3.2  BONUS. The Employee shall be eligible to receive a bonus of up to
30% of his base salary upon the achievement of annual objectives to be approved
by the CEO of the Company after discussion with the Employee. The Board shall
review the Employee's performance and determine the amount of the bonus, if any,
to be paid to the Employee.

          3.3  REIMBURSEMENT OF EXPENSES. The Company shall reimburse the
Employee for all reasonable travel, entertainment and other expenses incurred or
paid by the Employee in connection with, or related to, the performance of his
duties, responsibilities or services under this Agreement, upon presentation by
the Employee of documentation, expense statements, vouchers and/or such other
supporting information as the Company may request.

          3.4  FRINGE BENEFITS. The Employee shall be entitled to participate in
all other bonus and stock incentive programs that the Company establishes and
makes available to its other employees at the same level as the Employee to the
extent that Employee's position, tenure, salary, age, health and other
qualifications make him eligible to participate. The Employee shall be entitled
to 12 days paid vacation per year, to be taken at such times as may be approved
by David Stack (or the Board or its designee).

     4.   EMPLOYMENT TERMINATION. The employment of the Employee by the Company
pursuant to this Agreement shall terminate upon the occurrence of any of the
following:

                                       3
<PAGE>   4

          4.1  EXPIRATION OF EMPLOYMENT PERIOD. Expiration of the Employment
Period in accordance with Section 1.

          4.2  TERMINATION FOR CAUSE. At the election of the Company,
immediately upon written notice by the Company to the Employee, for "cause" as
determined by the Board. For purposes of this Section 4.2, "cause" for
termination shall be deemed to exist only if any of the following shall have
occurred:

     (a)  the Employee's conviction of any crime (whether or not involving the
Company) which constitutes a felony in the jurisdiction involved (other than
unintentional motor vehicle felonies);

     (b)  any act of theft, fraud, misappropriation of funds or embezzlement by
the Employee, in connection with his work with the Company, or any other act or
acts of dishonesty on the part of the Employee resulting or intended to result
directly or indirectly in personal gain or enrichment of the Employee at the
expense of the Company;

     (c)  the Employee's failure to perform in all material respects the
services required to be performed pursuant to Section 2 of this Agreement,
PROVIDED THAT if such failure is capable of being corrected, such failure
continues uncorrected for a period of thirty (30) days after the Employee shall
have received written notice from the Company stating with reasonably
specificity the nature of such failure;

     (d)  the Employee's breach of Sections 6, 7 or 8 of this Agreement;

     (e)  the Employee's excessive use of alcohol and/or drugs which is judged
by the CEO and the Board to materially interfere with the performance of his
duties; or

     (f)  any misconduct by the Employee which in the reasonable judgment of the
CEO and the Board would jeopardize the success of the Company.

                                       4
<PAGE>   5

          4.3  DEATH OR DISABILITY. Thirty (30) days after the death or
disability of the Employee. As used in this Agreement, the term "disability"
shall mean the inability of the Employee, due to a physical or mental
disability, for a period of ninety (90) days, whether or not consecutive, during
any 360-day period to perform the services contemplated under this Agreement. A
determination of disability shall be made by a physician satisfactory to both
the Employee and the Company, PROVIDED THAT if the Employee and the Company do
not agree on a physician, the Employee and the Company shall each select a
physician and these two together shall select a third physician, whose
determination as to disability shall be binding on all parties.

          4.4  VOLUNTARY TERMINATION. At the election of either party, upon
written notice of termination given at least ninety (90) days prior to the
effective date of termination.

          4.5  VOLUNTARY TERMINATION FOR "GOOD REASON." At the election of the
Employee, upon at least 30 days prior written notice to the Company, for "Good
Reason," which shall be deemed to exist only if:

     (i)  if the Company fails to comply in any material respect with the
provisions of Section 3, other than an isolated, insubstantial and inadvertent
failure which is remedied by the Company promptly after receipt of notice
thereof given by the Employee;

     (ii) the Company shall require the Employee to be based at a location that
is more than 50 miles from Parsippany, New Jersey

          4.6  ANGIOMAX TERMINATION. At any time after September 1, 2000, at the
election of either party, upon written notice of termination given at least
thirty (30) days prior to the effective date of termination, if the Company has
not received written

                                       5
<PAGE>   6

notice of FDA approval of, or an approvable letter from the FDA (which does not
require additional clinical trials on the part of the Company) with respect to,
the Company's Angiomax product currently being reviewed by the FDA.

     5.   EFFECT OF TERMINATION.

          5.1  TERMINATION FOR CAUSE OR AT ELECTION OF EMPLOYEE. In the event
the Employee's employment is terminated for cause pursuant to Section 4.2, at
the election of the Employee pursuant to Section 4.4 or 4.5(iii), or at the
election of either party pursuant to Section 4.6, the Company shall pay to the
Employee all sums otherwise payable to him under Section 3 through the last day
of his actual employment by the Company.

          5.2  TERMINATION FOR DEATH OR DISABILITY. If the Employee's employment
is terminated by death or because of disability pursuant to Section 4.3, the
Company shall pay to the estate of the Employee or to the Employee, as the case
may be, all sums which would otherwise be payable to the Employee under Section
3 up to the end of the month in which the termination of his employment because
of death or disability occurs.

          5.3  TERMINATION FOR GOOD REASON OR AT ELECTION OF COMPANY. In the
event that Employee's employment is terminated by the Employee for "Good Reason"
pursuant to Section 4.5(i) or (ii), or at the election of the Company pursuant
to Section 4.4, the Company shall continue to pay to the Employee the salary set
forth in Section 3.1, and shall continue to make available to the Employee the
benefits set forth in Section 3.3, excluding vacation days and bonus sums under
said Section 3.3 accrued during this period, until the later of (a) the first
anniversary of the Commencement Date of this Agreement, or (b) three (3) months
after the date of termination, but in no event later than

                                       6
<PAGE>   7

such date as the Employee shall have commenced full-time employment with a new
employer.

          5.4  SURVIVAL. The provisions of Sections 6 and 7 shall survive the
termination of this Agreement.

     6.   NON-COMPETE.

          6.1  NON-COMPETE RESTRICTIONS During the Employment Period and for a
period of one (1) year after the termination or expiration thereof (such one (1)
year period being inapplicable in the event of a termination pursuant to Section
4.4 at the election of the Company or by the Employee pursuant to Section 4.5(a)
or (b)), the Employee will not directly or indirectly as an individual
proprietor, partner, officer, consultant, employee, director, joint venturer, or
in any other similar capacity engage in the business of developing, producing,
marketing or selling (or assist any other person engaging in the business of
developing, producing, marketing or selling) any Competitive Products. For this
purpose, "Competitive Products" shall mean any drugs or devices used to
diagnose, prevent or treat arterial or venous thrombosis, including, without
limitation:

-    Factor 7 inhibitors

-    Factor Xa inhibitors

-    Indirect thrombin inhibitors (e.g. heparin, any low molecular weight or
     otherwise fractionated heparin etc.)

-    Direct thrombin inhibitors (e.g. hirudins [Revasc(R), Refludan(R)],
     argatroban [Novastan], malagatran, naragaptran etc.)

-    Orally active platelet inhibitors including aspirin, ADP antagonists (e.g.
     Plavix(R), Ticlid(R)) oral GP2b-3a inhibitors etc.)

-    Intravenous platelet inhibitors (e.g. GP2b-3a inhibitors, Reopro(R),
     Aggrastat(R), Integrelin(R) etc.)

-    Fibrinolytics (e.g. streptokinase, urokinase, tPA, tPA analogues such as
     TNK, staphylokinase etc.).

                                       7
<PAGE>   8

          6.2  LIMITATIONS. Notwithstanding the provisions of Section 6.1, it is
recognized that the Employee's primary experience is in the pharmaceutical
industry, and that his ability to earn a livelihood is likely to be dependent on
future employment in such industry. Accordingly, the Company agrees that the
employment of the Employee by a pharmaceutical company in a position in which he
assumes responsibility for multiple products, most of which are not Competitive
Products, shall not be considered a violation of Section 6.1, so long as (i) the
Employee's responsibilities in such position are not directed principally to
Competitive Products, (ii) the portfolio of the pharmaceutical company which
hires the Employee must contain the Competitive Products prior to the hiring of
the Employee, and (iii) the pharmaceutical company which hires the Employee has
been in existence for at least five (5) years prior to hiring the Employee.

          6.3  EXTENSION. If the Employee violates the provisions of Section
6.1, the Employee shall continue to be bound by the restrictions set forth in
this Section 6 until a period of one year has expired without any violation of
such provision.

          6.4  CUTBACK CLAUSE. If any restriction set forth in this Section 6 is
found by any court of competent jurisdiction to be unenforceable because it
extends for too long a period of time or over too great a range of activities or
in too broad a geographic area, it shall be interpreted to extend only over the
maximum period of time, range of activities or geographic area as to which it
may be enforceable.

          6.5  EQUITABLE REMEDIES. The restrictions contained in this Section 6
are necessary for the protection of the business and goodwill of the Company and
are considered by the Employee to be reasonable for such purpose. The Employee
agrees that any breach of Section 6.1 is likely to cause the Company substantial
and irrevocable damage and therefore, in the event of any such breach, the
Employee agrees that the

                                       8
<PAGE>   9

Company, in addition to such other remedies which may be available, shall be
entitled to specific performance and other injunctive relief.

     7.   NON-SOLICITATION.

          7.1  NON-SOLICITATION RESTRICTIONS. While the Employee is employed by
the Company and for a period of one (1) year after the termination or cessation
of such employment for any reason, the Employee will not directly or indirectly
recruit, solicit or hire any employee of the Company, or induce or attempt to
induce any employee of the Company to terminate his/her employment with, or
otherwise cease his/her relationship with, the Company (other than David Stack,
Fred Ryan, or Melinda Popolla). If the Employee violates the provisions of this
Section 7.1, the Employee shall continue to be bound by the restrictions set
forth in this Section 7.1 until a period of one (1) year has expired without any
violation of such provisions.

          7.2  CUTBACK CLAUSE. If any restriction set forth in Section 7.1 is
found by any court of competent jurisdiction to be unenforceable because it
extends for too long a period of time or over too great a range of activities or
in too broad a geographic area, it shall be interpreted to extend only over the
maximum period of time or range of activities as to which it may be enforceable.

          7.3  EQUITABLE REMEDIES. The restrictions contained in Section 7.1 are
necessary for the protection of the business and goodwill of the Company and are
considered by the Employee to be reasonable for such purpose. The Employee
agrees that any breach of Section 7 is likely to cause the Company substantial
and irrevocable damage and therefore, in the event of any such breach, the
Employee agrees that the Company, in addition to such other remedies which may
be available, shall be entitled to specific performance and other injunctive
relief.

                                       9
<PAGE>   10

     8.   INVENTIONS AND PROPRIETARY INFORMATION.

          8.1  INVENTIONS.

          (a) The Employee will make full and prompt disclosure to the Company
of all inventions, improvements, discoveries, methods, developments, software
and works of authorship, whether patentable or not, which are created, made,
conceived or reduced to practice by him or under his direction or jointly with
others, for the benefit of the Company (all of which are collectively referred
to in this Agreement as "Developments") during the Employment Period which
Developments are directly related to the services performed by the Employee
hereunder.

          (b) The Employee agrees to assign and does hereby assign to the
Company (or any person or entity designated by the Company) all its right, title
and interest in and to all Developments and all related patents, patent
applications, copyrights and copyright applications.

          (c) Notwithstanding the foregoing, this Agreement shall not require
assignment or disclosure of any Developments that: (i) the Employee develops
outside of this Agreement without using the Company's equipment, supplies,
facilities, or Proprietary Information (as defined below); (ii) do not directly
result from the specific services that the Employee performs for the Company
during the Employment Period; or (iii) do not relate to the business or research
of the Company, as disclosed to the Employee as of the date of this Agreement,
which disclosure may be modified or supplemented by written notice to the
Employee from time to time.

          (d) The Employee agrees to cooperate fully with the Company, both
during and after the term of this Agreement, with respect to the procurement,
maintenance and enforcement of copyrights, patents and other intellectual
property rights

                                       10
<PAGE>   11

(both in the United States and foreign countries) relating to Developments,
except as provided above. The Employee shall sign all papers, including, without
limitation, copyright applications, patent applications, declarations, oaths,
formal assignments, assignments of priority rights and powers of attorney, which
the Company may deem necessary or desirable in order to protect its rights and
interests in any Developments.

          8.2  PROPRIETARY INFORMATION.

          (a) The Employee agrees that all information, whether or not in
writing, of a private, secret or confidential nature concerning the Company's
business, business relationships or financial affairs (collectively, "the
Company's Proprietary Information") which is disclosed to the Employee is and
shall be the exclusive property of the Company. By way of illustration, but not
limitation, the Company's Proprietary Information may include inventions,
products, developments, plans, research data, clinical data, financial data,
personnel data, computer programs, customer and supplier lists and contacts at
or knowledge of customers or prospective customers of the Company. The Employee
will not disclose any of the Company's Proprietary Information to any person or
entity other than employees of the Company on a need-to-know basis under this
Agreement or use the same for any purposes (other than in the performance of its
duties) without written approval by an officer of the Company, either during or
after the term of this Agreement unless and until such of the Company's
Proprietary Information has become public knowledge without fault by the
Employee.

          (b) The Employee agrees that all files, letters, memoranda, reports,
records, data, sketches, drawings, laboratory notebooks, program listings or
other written, photographic or other tangible material containing the Company's
Proprietary Information relating to the services performed hereunder, whether
created by the

                                       11
<PAGE>   12

Employee or others during the Employment Period, shall be and are the exclusive
property of the Company. All such materials or copies thereof and all tangible
property of the Company in the custody or possession of the Employee shall be
delivered to the Company upon the earlier of (i) a request by the Company; or
(ii) termination of this Agreement. After such delivery, the Employee shall not
retain any such materials or copies thereof or any such tangible property,
except one copy for archival purposes.

          (c) The parties agree that their obligation not to disclose or to use
information and materials of the types set forth in paragraphs (a) and (b)
above, and their obligation to return materials and tangible property, set forth
in paragraph (b) above, also extends to such types of information, materials and
tangible property of customers or suppliers of the Company, or other third
parties who may have disclosed or entrusted the same to the Company.

          (d) The parties' obligations under this Section 8.2 shall not apply to
any information that (i) is or becomes known to the general public under
circumstances involving no breach by the parties of the terms of this Section
8.2; (ii) is generally disclosed to third parties by the Company without
restriction on such third parties; (iii) was known to Company or the Employee as
of the date of this Agreement as evidenced by documents in possession of Company
or the Employee; or (iv) is approved for release by written authorization of the
Company or the Employee.

          (g) The Employee represents that his employment by the Company and his
performance under this Agreement does not, and shall not breach any agreement
that obligates him to keep in confidence any of his trade secrets or
confidential or proprietary information or of any other party or to refrain from
competing, directly or indirectly, with

                                       12
<PAGE>   13

the business of any other party. The Employee shall not disclose to the Company
any trade secrets or confidential or proprietary information of any other party.

          (h) The Employee acknowledges that as of the date hereof the Company
has agreements with other persons or with the United States Government, or
agencies thereof, that impose obligations or restrictions on the Company
regarding inventions made during the course of work under such agreements or
regarding the confidential nature of such work. The Employee agrees to be bound
by all such obligations and restrictions that are known to it and to take all
action necessary to discharge the obligations of the Company under such
agreements.

          8.3  REMEDIES. The parties acknowledge that any breach of the
provisions of this Section 8 shall result in serious and irreparable injury to
the non-breaching party for which the parties cannot be adequately compensated
by monetary damages alone. The parties agree, therefore, that, in addition to
any other remedy they may have, the Company shall be entitled to enforce the
specific performance of this Agreement against the Employee and to seek both
temporary and permanent injunctive relief (to the extent permitted by law)
without the necessity of proving actual damages in any federal or state court
within Massachusetts and the Employee shall be entitled to enforce the specific
performance of the Agreement against the Company and to seek both temporary and
permanent injunctive relief (to the extent permitted by law) without the
necessity of proving actual damages in any federal or state court within
Massachusetts.

     9.   OTHER AGREEMENTS. Employee hereby represents that he is not bound by
the terms of any agreement with any previous employer or other party to refrain
from using or disclosing any trade secret or confidential or proprietary
information in the course of his employment with the Company or to refrain from
competing, directly or

                                       13
<PAGE>   14

indirectly, with the business of such previous employer or any other party.
Employee further represents that his performance of all the terms of this
Agreement and as an employee of the Company does not and will not breach any
agreement to keep in confidence proprietary information, knowledge or data
acquired by him in confidence or in trust prior to his employment with the
Company.

     10.  NOTICES. All notices required or permitted under this Agreement shall
be in writing and shall be deemed effective upon personal delivery or upon
deposit in the United States Post Office, by registered or certified mail,
postage prepaid, addressed to the other party at the address shown above, or at
such other address or addresses as either party shall designate to the other in
accordance with this Section 9.

     11.  PRONOUNS. Whenever the context may require, any pronouns used in this
Agreement shall include the corresponding masculine, feminine or neuter forms,
and the singular forms of nouns and pronouns shall include the plural, and vice
versa.

     12.  ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
between the parties and supersedes all prior agreements and understandings,
whether written or oral, relating to the subject matter of this Agreement.
Reference is also made to the Non-Statutory Stock Option Agreement between the
Employee and the Company dated of even date herewith.

     13.  AMENDMENT. This Agreement may be amended or modified only by a written
instrument executed by both the Company and the Employee.

     14.  GOVERNING LAW. This Agreement shall be construed, interpreted and
enforced in accordance with the laws of the Commonwealth of Massachusetts.

     15.  SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and inure
to the benefit of both parties and their respective successors and assigns,
including any

                                       14
<PAGE>   15

entity with which or into which the Company may be merged or which may succeed
to its assets or business, provided, however, that the obligations of the
Employee are personal and shall not be assigned by him.

     16.  MISCELLANEOUS.

          16.1 NO WAIVER. No delay or omission by the Company in exercising any
right under this Agreement shall operate as a waiver of that or any other right.
A waiver or consent given by the Company on any one occasion shall be effective
only in that instance and shall not be construed as a bar or waiver of any right
on any other occasion.

          16.2 CAPTIONS. The captions of the sections of this Agreement are for
convenience of reference only and in no way define, limit or affect the scope or
substance of any section of this Agreement.

          16.3 ENFORCEABILITY. In case any provision of this Agreement shall be
invalid, illegal or otherwise unenforceable, the validity, legality and
enforceability of the remaining provisions shall in no way be affected or
impaired thereby.

          16.4 COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall be deemed to be an original, but all of which
shall be one and the same document.

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year set forth above.

                                          THE MEDICINES COMPANY

                                          By: /s/ Clive A. Meanwell
                                             ----------------------------------
                                          Title: President
                                                -------------------------------

                                       15
<PAGE>   16

                                             /s/ Thomas Quinn
                                            -----------------------------------
                                            Thomas Quinn

                                       16

<PAGE>   17
                      MODIFICATION TO EMPLOYMENT AGREEMENT

     This Modification to the Employment Agreement dated April 1, 2000 by and
between The Medicines Company, a Delaware Corporation with its principal place
of business at One Cambridge Center, Cambridge, Massachusetts 02142 and Thomas
Quinn, residing at 325 Independence Drive, Orchard Park, New York 14127 is as
follows:

     New paragraphs 4.5(iii) and 4.5(iv) are added as set forth below:

     (iii) David Stack shall have ceased to serve as Senior Vice President of
     the Company; or

     (iv) a failure by Employer to provide infrastructure support either under
     the Stack Pharmaceutical Services Agreement dated April 1, 2000 or through
     other means acceptable to Employee.

     IN WITNESS WHEREOF, the parties hereto have executed this Modification to
Employment Agreement this 13th day of April, 2000.

                                          THE MEDICINES COMPANY

                                          By: /s/ Clive A. Meanwell
                                             ---------------------------------
                                          Title: Chief Executive Officer
                                                ------------------------------

                                              /s/ Thomas Quinn
                                              --------------------------------
                                              Thomas Quinn
<PAGE>   18
                                    AGREEMENT

     This Amendment to Employment Agreement (the "Amendment"), made as of the
1st day of June, 2000, is entered into by The Medicines Company, a Delaware
corporation with its principal place of business at One Cambridge Center,
Cambridge, Massachusetts 02142 (the "Company"), and Thomas Quinn, residing at
325 Independence Drive, Orchard Park, New York 14127 (the "Employee").

     WHEREAS, the Company and the Employee are parties to an Employment
Agreement dated as of April 1, 2000, as amended by a modification dated April
13, 2000 (the "Employment Agreement"); and

     WHEREAS, the Company and the Employee desire to make certain amendments to
the terms of the Employment Agreement;

     NOW THEREFORE, in consideration of these premises, the mutual covenants and
promises contained herein, and other good and valuable consideration, the
receipt and sufficiency of which are acknowledged, the parties hereto agree as
follows:

I.   Employment Agreement

     1.   DEFINED TERMS. The capitalized terms used herein but not otherwise
defined shall have the meanings assigned to them in the Employment Agreement.

     2.   TITLE; CAPACITY. The Employment Agreement is hereby amended by
deleting Section 2 of the Employment Agreement in its entirety and inserting in
lieu thereof the following:

                    "2.  TITLE; CAPACITY. The Employee shall serve as Vice
                         President or in such other position as the Company or
                         its Board of Directors (the "Board") may determine from
                         time to time The Employee shall be based at the offices
                         of Stack Pharmaceuticals, Inc., 5 Sylvan Way,
                         Parsippany, New Jersey, unless otherwise agreed by the
                         parties. The Employee shall be subject to the
                         supervision of, and shall have such authority as is
                         delegated to him by David Stack, Senior Vice President
                         of the Company (or such other officer of the Company as
                         may be designated by the Board).

                              The Employee hereby accepts such employment and
                         agrees to undertake the duties and responsibilities
                         inherent in such position and/or such other duties and
                         responsibilities as David Stack (or the Board or its
                         designee) shall from time to time reasonably assign to
                         him. The Employee agrees to devote his or her full
                         business time, attention and energies to the business
                         and interests of the Company during the Employment
                         Period. The Employee agrees to abide by the rules,
                         regulations, instructions, personnel practices and
                         policies of the Company and any changes therein which
                         may be adopted from time to time by the Company

<PAGE>   19

                         except as provided in these agreements. The Employee
                         acknowledges receipt of copies of all such rules and
                         policies committed to writing as of the date of this
                         Agreement."

     3.   SALARY. Section 3.1 of the Employment Agreement is hereby amended by
deleting the amount "$120,000" and inserting in lieu thereof "$190,000."

     4.   BONUS. Section 3.2 of the Employment Agreement is hereby amended by
deleting "30%" and inserting in lieu thereof "40%."

II.  Miscellaneous Provisions

     1.   The captions of the sections of this Amendment are for convenience of
reference only and in no way define, limit, or affect the scope or substance of
any section of this Amendment.

     2.   This Amendment shall be construed, interpreted, and enforced in
accordance with the laws of the Commonwealth of Massachusetts, without giving
effect to conflict of laws provisions.

     3.   This Amendment, together with the Employment Agreement, constitute the
entire agreement between the parties and supersedes all prior agreements and
understandings, whether written or oral, relating to the subject matter hereof.

     4.   In all respects other than as specifically provided in this Amendment,
the Employment Agreement is hereby ratified and affirmed.

                     [Remainder of page intentionally blank]

                                     - 2 -
<PAGE>   20

     In witness whereof, the parties hereto have executed this Amendment as of
the day and year set forth above.

                                        THE MEDICINES COMPANY

                                   By:  /s/ Clive A. Meanwell
                                       -----------------------------------------

                                   Title:  President and Chief Executive Officer
                                          --------------------------------------

                                   EMPLOYEE

                                    /s/ Thomas Quinn
                                   ---------------------------------------------
                                   Thomas Quinn

                                     - 3 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}]]